"MannKind (NASDAQ:MNKD) earns a D this week, moving down from last week’s grade of C. MannKind is a biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The stock also gets an F in Cash Flow. The stock price has fallen 36.8% over the past month, worse than the 6% decrease the Nasdaq has seen over the same period of time. As of Oct. 24, 2012, 14.8% of outstanding MannKind shares were held short. For more information, get Portfolio Grader’s complete analysis of MNKD stock."

http://investorplace.com/2012/10/5-biotechnology-stocks-to-sell-now-plx-mnkd-halo/